Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bhakti Mehta

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pediatric Transplantation|April 8, 2015
Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous diseaseBhakti Mehta, Kris Mahadeo, Neena Kapoor, et al.
Pediatric Hematology and Oncology|August 31, 2013
Inflammatory myofibroblastic tumors in childhoodBhakti Mehta, Leo Mascarenhas, Shengmei Zhou, et al.
Neuromolecular Medicine|December 18, 2012
Novel mutations in cyclin-dependent kinase-like 5 (CDKL5) gene in Indian cases of Rett syndromeDhanjit Kumar Das, Bhakti Mehta, Shyla R Menon, et al.
British Journal of Haematology|May 24, 2016
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysisSophie Park, Pierre Fenaux, Peter Greenberg, et al.
American Journal of Hematology|September 29, 2018
Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line settingLauren C Bylsma, Jon P Fryzek, Karynsa Cetin, et al.
British Journal of Haematology|February 23, 2019
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studiesDavid J Kuter, Adrian Newland, Beng H Chong, et al.
Haematologica|March 9, 2019
Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopeniaMichael D Tarantino, James B Bussel, Victor S Blanchette, et al.
The Lancet. Haematology|February 4, 2018
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trialHagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLCMaximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pediatric Transplantation|April 8, 2015
Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous diseaseBhakti Mehta, Kris Mahadeo, Neena Kapoor, et al.
Pediatric Hematology and Oncology|August 31, 2013
Inflammatory myofibroblastic tumors in childhoodBhakti Mehta, Leo Mascarenhas, Shengmei Zhou, et al.
Neuromolecular Medicine|December 18, 2012
Novel mutations in cyclin-dependent kinase-like 5 (CDKL5) gene in Indian cases of Rett syndromeDhanjit Kumar Das, Bhakti Mehta, Shyla R Menon, et al.
British Journal of Haematology|May 24, 2016
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysisSophie Park, Pierre Fenaux, Peter Greenberg, et al.
American Journal of Hematology|September 29, 2018
Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line settingLauren C Bylsma, Jon P Fryzek, Karynsa Cetin, et al.
British Journal of Haematology|February 23, 2019
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studiesDavid J Kuter, Adrian Newland, Beng H Chong, et al.
Haematologica|March 9, 2019
Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopeniaMichael D Tarantino, James B Bussel, Victor S Blanchette, et al.
The Lancet. Haematology|February 4, 2018
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trialHagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLCMaximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
Pageof 2